Women without regular medical care at increased risk of ovarian cancerMarch 27, 2007In North America, ovarian cancer is the second most common gynecological cancer and is the leading cause of death among women with gynecological cancer. The high mortality is in part due to the difficulty of detecting and diagnosing this condition at an early stage. In this case-control study, Abenhaim and colleagues examined whether the frequency of medical visits and pelvic examinations and the type of health care provider visited had an effect on the risk of ovarian cancer. They found that women who did not have an annual medical visit or pelvic examination and who had no regular health care provider were at an increased risk of ovarian cancer. This risk was most pronounced among postmenopausal women. Although the study could not determine whether women who sought regular health care and had a regular physician were at a decreased risk of ovarian cancer, the most prudent recommendation is that women, especially those who are postmenopausal, should be encouraged to maintain regular health care. Canadian Medical Association Journal | |||||||||||||||||||||
|
Related Ovarian Cancer Current Events and Ovarian Cancer News Articles Study unmasks how ovarian tumors evade immune system Scientists at Johns Hopkins have determined how the characteristic shedding of fatty substances, or lipids, by ovarian tumors allows the cancer to evade the body's immune system, leaving the disease to spread unchecked Jefferson Department of Surgery announces new pancreas tumor registry Charles J. Yeo, M.D., Samuel D. Gross Professor and Chair, Department of Surgery at Jefferson Medical College of Thomas Jefferson University, announces the establishment of the new Jefferson Pancreas Tumor Registry (JPTR). Disease diagnosis in just 15 minutes Testing for diseases such as cancer and multiple sclerosis could soon be as simple as using a pregnancy testing kit. Bio-imaging mass spectrometry techniques reveal molecular details about complex systems Understanding biology at the systems level is difficult, especially when studying complex specimens like tissue slices or communities of organisms in a biofilm. Scientists must be able to identify, quantify and locate the molecules present in the samples. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells A research team, led by investigators at the Department of Surgery at Jefferson Medical College of Thomas Jefferson University and the Kimmel Cancer Center at Jefferson, has achieved a substantial "kill" of pancreatic cancer cells by using nanoparticles to successfully deliver a deadly diphtheria toxin gene. Promising new treatment option for women with recurrent ovarian cancer Combining the new drug trabectedin with pegylated liposomal doxorubicin provides clinical benefit to women with relapsed ovarian cancer, according to new results presented at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm. Risk of breast cancer mutations underestimated for Asian women, Stanford study shows Oncologist Allison Kurian, MD, and her colleagues at the Stanford University School of Medicine were perplexed. Computer models designed to identify women who might have dangerous genetic mutations that increase their risk of breast and ovarian cancer worked well for white women. But they seemed to be less reliable for another ethnic group. Cryopreservation techniques bring hopes for women cancer victims and endangered species Emerging cryopreservation techniques are increasing hope of restoring fertility for women after diseases such as ovarian cancer that lead to destruction of reproductive tissue. Study challenges routine use of MRI scans to evaluate breast cancer A new study suggests women with newly-diagnosed breast cancer who receive an MRI after their diagnosis face delays in starting treatment and are more likely to receive a mastectomy. Variation of normal protein could be key to resistance to common cancer drug Researchers at the Moores Cancer Center at the University of California, San Diego (UC SD) in La Jolla have found evidence explaining why a common chemotherapy drug, cisplatin, may not always work for every cancer patient. They have shown that when a variant version of a key protein that normally causes cell death is active, patients may be resistant to the cancer-killing drug. More Ovarian Cancer Current Events and Ovarian Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||